Insider: Leversage Jill Director - Aurinia Pharmaceuticals Inc.
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 12,918 | 400 | 13,318 |
| Value | $169,742.52 | $5,256.00 | $174,998.52 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 05/21/2024 | DDS | 5,610 | Direct | COM | $5.74 | $32,201.40 | 12,918 |
| 05/23/2023 | DDS | 4,815 | Direct | COM | $11.26 | $54,216.90 | 18,528 |
| 12/13/2021 | AAP | 1,600 | Direct | COM | $20.04 | $32,064.00 | 5,300 |
| 05/11/2021 | AAP | 2,500 | Direct | COM | $10.96 | $27,389.25 | 3,700 |
| 01/29/2021 | AAP | 400 | Indirect | COM | $16.03 | $6,412.00 | 400 |
| 01/29/2021 | AAP | 1,200 | Direct | COM | $16.03 | $19,236.00 | 1,200 |
| 1 You are at page 1 of 1 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2025 Zacks Investment Research